What drove Edwards Lifesciences' growth in Q2?

Strong global TAVR sales growth, along with expansion in mitral and tricuspid therapies, were the main drivers.

Did Edwards Lifesciences provide guidance?

No specific guidance was provided in the summary, but management expressed confidence in continued growth.

Edwards Lifesciences Q2 2026 Earnings Beat Estimates

Edwards Lifesciences reported second-quarter 2026 results that exceeded analyst expectations, with growth across all major business segments. The CEO cited strong demand for transcatheter aortic valve replacement (TAVR) and mitral/tricuspid therapies.

By: Wrqti Editorial

July 24, 2026

2 min read

Source: MarketBeat

Edwards Lifesciences (NYSE:EW) reported better-than-expected second-quarter 2026 results, driven by broad growth across transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical products. CEO Bernard Zovighian highlighted strong momentum across all segments.

Key Financial Results

Specific financial figures were not disclosed in the available summary, but management indicated results were "better than expected." A full earnings release is expected later.

Highlights from the Call

Strong global TAVR sales growth.
Expansion in mitral and tricuspid therapies.
Solid performance in surgical products.

Guidance

The company did not provide specific guidance in the summary, but management expressed confidence in continued growth.

Stock Impact

The stock reaction was not mentioned, but positive results typically support the stock.

What This Means for Investors

Edwards Lifesciences' results underscore strong demand for its innovative structural heart solutions. Investors should review the full earnings report for detailed financials.

Frequently Asked Questions

The company reported better-than-expected results, with growth across all major business segments including TAVR, TMTT, and surgical products.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.